NYSE:AMRX
Amneal Pharmaceuticals, Inc.
- Stock
Last Close
6.21
03/05 20:00
Market Cap
1.68B
Beta: 1.32
Volume Today
3.83M
Avg: 1.09M
PE Ratio
151.43
PFCF: 12.36
Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|
average inventory | 370.63M - | 419.14M 13.09% | 435.86M 3.99% | 490.02M 12.43% | 510.06M 4.09% | ||||
average payables | 292.23M - | 510.96M 74.85% | 560.57M 9.71% | 598.50M 6.77% | 560.77M 6.30% | ||||
average receivables | 432.53M - | 544.24M 25.83% | 623.23M 14.51% | 652.03M 4.62% | 703.03M 7.82% | ||||
book value per share | -3.36 - | 7.04 309.74% | 2.63 62.73% | 2.34 10.88% | 2.46 5.33% | 1.22 50.54% | |||
capex per share | -1.08 - | -0.99 8.29% | -0.76 23.31% | -0.74 3.33% | -0.45 39.14% | -0.35 21.26% | -0.60 69.80% | -0.25 59.12% | |
capex to depreciation | -3.77 - | -2.49 34.09% | -0.71 71.60% | -0.47 33.46% | -0.28 40.19% | -0.23 19.79% | -0.38 67.26% | -0.19 50.06% | |
capex to operating cash flow | -1.08 - | -0.49 54.94% | -0.39 20.48% | -57.14 14,628.10% | -0.17 99.69% | -0.22 24.65% | -1.39 539.30% | -0.13 91.01% | |
capex to revenue | -0.12 - | -0.11 9.66% | -0.06 47.19% | -0.06 2.61% | -0.03 44.55% | -0.03 24.31% | -0.04 62.88% | -0.02 55.91% | |
cash per share | 0.65 - | 1.68 159.70% | 1.14 31.75% | 2.32 102.30% | 1.66 28.14% | 0.17 89.66% | |||
days of inventory on hand | 204.29 - | 176.30 13.70% | 109.23 38.04% | 131.28 20.19% | 134.84 2.71% | 135.70 0.63% | |||
days payables outstanding | 50.36 - | 198.37 293.92% | 145.46 26.67% | 164.20 12.88% | 160.73 2.11% | 137.60 14.39% | |||
days sales outstanding | 135.15 - | 105.86 21.67% | 136.04 28.50% | 117.29 13.78% | 115.72 1.34% | 122.47 5.83% | |||
debt to assets | 1.11 - | 0.62 44.12% | 0.75 22.03% | 0.73 2.71% | 0.73 0.55% | 0.75 2.58% | |||
debt to equity | -3.85 - | 3.00 178.01% | 7.98 165.65% | 8.53 6.89% | 7.84 8.08% | 15.46 97.32% | |||
dividend yield | 0.13 - | 0.20 48.86% | 0.11 45.83% | ||||||
earnings yield | 0.14 - | 0.09 35.67% | -0.10 212.45% | -0.95 861.56% | 0.10 110.74% | 0.03 72.22% | -0.85 3,099.85% | -0.08 90.74% | |
enterprise value | 3.32B - | 4.20B 26.38% | 3.25B 22.58% | 3.27B 0.67% | 3.34B 2.09% | 3.12B 6.65% | |||
enterprise value over ebitda | 12.26 - | 10.10 17.60% | 46.58 361.11% | 9.38 79.87% | 7.55 19.50% | 6.98 7.48% | |||
ev to operating cash flow | 14.19 - | 16.78 18.28% | 1.91K 11,263.04% | 8.64 99.55% | 13.82 60.00% | 47.92 246.77% | |||
ev to sales | 3.21 - | 2.53 21.44% | 2.00 20.83% | 1.64 17.83% | 1.60 2.84% | 1.41 11.65% | |||
free cash flow per share | -0.08 - | 1.04 1,356.19% | 1.20 15.27% | -0.72 160.21% | 2.12 392.79% | 1.27 40.12% | -0.17 113.30% | 1.72 1,116.34% | |
free cash flow yield | -0.01 - | 0.06 1,099.67% | 0.09 41.85% | -0.15 269.02% | 0.46 408.81% | 0.27 42.87% | -0.08 132.00% | 0.28 433.20% | |
graham net net | -10.57 - | -20.85 97.18% | -19.10 8.39% | -17.59 7.87% | -17.34 1.44% | -18.17 4.77% | |||
graham number | 10.50 - | 14.54 38.44% | 16.43 12.99% | 4.95 69.88% | 2.74 44.62% | 6.80 148.28% | |||
income quality | 0.55 - | 1.38 151.74% | -1.24 189.88% | -0.00 99.77% | 5.53 195,741.49% | 11.99 116.94% | -0.26 102.13% | -7.09 2,676.00% | |
intangibles to total assets | 0 - | 0.05 Infinity% | 0.48 803.12% | 0.49 2.82% | 0.46 7.21% | 0.45 2.07% | 0.45 0.14% | 0 100% | |
interest coverage | 5.15 - | 3.45 33.07% | -0.14 103.97% | -0.82 496.23% | 0.62 176.42% | 1.53 145.83% | 1.30 15.06% | 0.01 99.59% | |
interest debt per share | 13.55 - | 22.28 64.47% | 22.21 0.30% | 20.94 5.74% | 20.23 3.38% | 19.90 1.63% | |||
inventory turnover | 1.79 - | 2.07 15.88% | 3.34 61.41% | 2.78 16.80% | 2.71 2.64% | 2.69 0.63% | |||
invested capital | -3.85 - | 3.00 178.01% | 7.98 165.65% | 8.53 6.89% | 7.84 8.08% | 15.46 97.32% | |||
market cap | 1.52B - | 1.91B 25.66% | 1.72B 9.97% | 636.75M 63.02% | 673.81M 5.82% | 713.34M 5.87% | 300.38M 57.89% | 1.07B 255.93% | |
net current asset value | -945.54M - | -2.17B 129.47% | -2.11B 2.80% | -2.11B 0.03% | -2.05B 2.70% | -2.18B 6.14% | |||
net debt to ebitda | 5.20 - | 5.96 14.54% | 37.46 528.45% | 7.45 80.12% | 5.94 20.27% | 6.31 6.30% | |||
net income per share | 1.81 - | 1.46 19.16% | -1.33 191.38% | -4.57 242.55% | 0.47 110.18% | 0.14 70.88% | -1.69 1,346.29% | -0.48 71.75% | |
operating cash flow per share | 1.00 - | 2.04 103.53% | 1.97 3.56% | 0.01 99.34% | 2.57 19,816.56% | 1.62 36.83% | 0.43 73.44% | 1.96 354.92% | |
payables turnover | 7.25 - | 1.84 74.61% | 2.51 36.37% | 2.22 11.41% | 2.27 2.16% | 2.65 16.81% | |||
receivables turnover | 2.70 - | 3.45 27.66% | 2.68 22.18% | 3.11 15.98% | 3.15 1.36% | 2.98 5.51% | |||
research and ddevelopement to revenue | 0.20 - | 0.19 7.66% | 0.13 31.85% | 0.12 1.72% | 0.10 23.10% | 0.10 4.65% | 0.09 9.66% | 0.07 24.25% | |
return on tangible assets | 0.13 - | -0.07 156.64% | -0.32 333.45% | 0.03 109.72% | 0.01 70.60% | -0.12 1,408.43% | |||
revenue per share | 8.86 - | 9.00 1.52% | 13.07 45.22% | 12.31 5.80% | 13.51 9.77% | 14.06 4.03% | 14.66 4.25% | 13.59 7.28% | |
roe | -0.43 - | -0.19 56.43% | -1.74 819.18% | 0.20 111.42% | 0.05 72.35% | -1.38 2,619.65% | |||
roic | 0.21 - | -0.01 102.53% | -0.12 2,052.59% | -0.05 55.80% | 0.04 177.91% | 0.07 68.45% | |||
sales general and administrative to revenue | 0.12 - | 0.11 9.55% | 0.14 31.35% | ||||||
shareholders equity per share | -3.36 - | 7.04 309.74% | 2.63 62.73% | 2.34 10.88% | 2.46 5.33% | 1.22 50.54% | |||
stock based compensation to revenue | 0.02 - | 0.00 78.31% | 0.10 2,110.78% | 0.01 86.77% | 0.01 21.87% | 0.01 30.31% | 0.01 6.08% | 0.01 22.16% | |
tangible asset value | -446.63M - | -1.18B 165.29% | -1.46B 22.84% | -1.48B 1.86% | -1.39B 6.04% | -1.49B 6.68% | |||
tangible book value per share | -3.89 - | -9.31 139.45% | -11.02 18.33% | -10.05 8.74% | -9.35 6.97% | -9.84 5.25% | |||
working capital | 475.05M - | 732.79M 54.26% | 659.80M 9.96% | 874.64M 32.56% | 842.87M 3.63% | 659.02M 21.81% |
All numbers in USD (except ratios and percentages)